978 results about "Diagnosis laboratory" patented technology

Devices and methods for performing a point of care blood, cell, and/or pathogen count or a similar blood test. Disclosed herein are systems that can be used to provide rapid, accurate, affordable laboratory-quality testing at the point of care. The systems described herein are capable of imaging and counting individual cells in a prepared cell sample (e.g., a peripheral blood smear or a blood sample prepared in a microfluidic device) or another prepared cell-containing sample without the need for a microscope or other expensive and cumbersome optics. The systems described herein are designed to eliminate or replace expensive, centralized clinical testing equipment and technical personnel. Such systems may include automated data reporting and decision support.

Systems and methods are provided for collecting, preparing, and/or analyzing a biological sample. A sample collection site may be utilized with one or more sample processing device. The sample processing device may be configured to accept a sample from a subject. The sample processing device may perform one or more sample preparation step and/or chemical reaction involving the sample. Data related to the sample may be sent from the device to a laboratory. The laboratory may be a certified laboratory that may generate a report that is transmitted to a health care professional. The health care professional may rely on the report for diagnosing, treating, and/or preventing a disease in the subject.

The lack of safe, reliable, automated and clinically acceptable blood sampling has been the main problem precluding the development of real-time systems for blood analysis and subsequent closed-loop physiological function control. While the analysis of a static blood sample in laboratory conditions has been rapidly advancing in reliability and blood volume reduction, non-invasive real-time blood analysis performed in vivo (while the blood is circulating in the body) has been elusive and unreliable. In this study we propose an innovative idea for semi-invasive blood sampling and analysis, which resembles the operation of a mosquito. At a miniature scale the proposed system does penetrate the skin to extract a static blood sample for further analysis, but the extent of this penetration, and the fact that it can be made painless, is particularly attractive for such applications as automated glucose analysis for closed-loop control of insulin infusion (artificial pancreas), continuous drug monitoring, or even periodic DNA analysis for security and identification purposes. These design aspects are described, and a specific implementation, applying MEMS (Micro Electro Mechanical Systems) technology, is suggested. The proposed microsystem is a matrix of individually controllable e-Mosquito™ cells, packaged in a disposable patch and attached to the skin, could be an avenue for real-time semi-invasive blood analysis and diagnostics.

A system is provided that integrates of records of clinical laboratory services into the assessment and optimization of patient health care and, in particular, regulation of the use of pharmaceuticals. Laboratory test result records are used in conjunction with other health care benefits records to monitor regulation of use of pharmaceuticals by patients. The incorporation of laboratory tests and results into such a utilization system allows improvement in the management of a patient's therapy based on a more precise picture of the patient's level of illness as revealed by the laboratory test results. The system of the present invention also allows optimization of the selection of laboratory tests to be performed, and also provides an outcome assessment of the risk of hospitalization due to pharmaceutical treatments resulting in physician intervention, leading to a change in physician prescribing behavior and, accordingly, a decrease in drug induced hospitalizations and improved quality of patient care and savings of health care costs.

The invention relates to a biological sample detection vehicle and a vehicular detection system thereof. At present, a mobile lab achieving biosafety level-3 protection level is developed at home and abroad, which is called 'P3 vehicle' commonly, conventional home and abroad P3 vehicle is formed by grouping more than 2 box-type vehicles, and has large size and complicated operation. The invention aims at providing a miniature biological sample detection vehicle which has excellent maneuvering characteristic and biosafety protection function, adapts to epidemic situations or public health incidents and consists of a cockpit (1), a front cabin (9), a rear cabin (22) and an atmosphere sampler (19), wherein the front cabin is an equipment cabin, and the rear cabin is an experimental cabin. The biological sample detection vehicle integrates biological sampling, air pre-alarming and quick detection into a whole, has good maneuvering property and matched functions, has the function of carrying out various biological sampling and pathogenic microorganism detection in the field of epidemic situation in remote rural areas or urban roadways, and can be used for executing a 'bio-control' quick detection task in contingency medical rescue with high efficiency.

The invention provides an early death risk assessment model establishing method and device based on ensemble learning. The method and device are used for assessing the death risk of an old multi-organfailure patient during hospitalization based on diagnosis and treatment data of the first day when the old multi-organ failure patient enters an intensive care unit. The method comprises the steps ofdata set construction, data processing and model construction and evaluation. The method comprises the following steps: acquiring three pieces of demographic information, five pieces of vital sign information, five laboratory examination indexes and two clinical indexes of a patient on the first day during living in an intensive care unit; inputting the data into a risk assessment device, and carrying out internal data preprocessing, feature calculation and model operation. Finally, the risk of adverse outcomes in the hospital of the patient can be predicted early, and doctors are helped to treat the patient as soon as possible.

The invention relates to a capsule or chip or sensor comprising a marker/detector and signalling device/method associated with the development of a medical condition/disease and to its use. This In Situ Lab On a Chip Signalling device (ISLOGS device) is used for detecting a medical condition/disease in situ or in vivo (inside the body), for example by swallowing it for testing in the digestive tract or by putting it into the vagina, mouth or nose. All reactions takes place in the body and when the test result is positive the device will notify the subject by colorizing the tested body fluid or biomaterial (for example faeces, urine or saliva) or the device itself. The detection is made outside of the body when the biomaterial or ISLOCS device has left the body.

The bacterial colony number sample for verifying food microbiological capacity relates to quality control technology in microbiological detection. The sample is matrix with added Bacillus cereus as leading bacteria and background bacteria. The matrix is practical food, and the background bacteria include one or several kinds of serratia marcescens, Citrobacter freundii, enteroaerogen and escherichia coli. The sample of the present invention has homogeneous colony number content, high finishing rate, and high stability, and may be used in test capacity verification of domestic and international labs. In the same time, the capacity verifying sample may be used in verification of detection method, calibration of test instrument, quality control and check of test result and other aspects.

We have successfully sequenced and cloned the gene expressing the Major Surface Protein 5 (MSP5) of A. phagocytophilum. The recombinant MSP5 (rMSP5) protein has been tested using sera from humans and dogs infected with A. phacytophilum. The polypeptide has been found to be immunogenic and useful as a diagnostic test antigen. The polypeptide antigen of the subject invention can provide the basis of a diagnostic assay that would allow the rapid, in-house, laboratory diagnosis of infection with A. phagocytophilum using a sample (e.g., serum, plasma, or whole blood) from an infected human or animal. Additionally, the subject invention provides methods of detecting the presence of A. phagocytophilum in biological or environmental samples utilizing antibodies provided by the subject invention. Furthermore, the use of the single antigen in the diagnosis of this important disease offers many advantages including enhanced test specificity, ease of testing and consistency of results using synthetically produced test antigens instead of cultured, whole organisms.

A medical diagnosis decision support system for assisting a health professional to diagnose a medical condition. The system is first provided with an anchor condition that can be a symptom, a sign, a laboratory test result, or an imaging test results or any combination thereof The system then guides users in a series of predetermined phases regarding abstract or concrete diagnosis groups that should be considered and appropriate data that should be collected during the clinical investigation process. The system suggests history and physical examination clinical data items, laboratory, and imaging tests that should be collected in order to differentiate among alternative diagnoses. In each phase, possible diagnoses are listed and ranked.

A real-time isothermal recombinase-polymerase amplification detection kit for African swine fever viruses is disclosed. A forward primer sequence for detecting the African swine fever viruses through a method provided by the kit is shown as SEQ ID NO:1, a reverse primer sequence is shown as SEQ ID NO:2 and a probe sequence is shown as SEQ ID NO:3. A real-time isothermal recombinase-polymerase amplification method provided by the invention for ASFV detection is simple and convenient in operation, rapid in reaction and low in detection cost, can be used for ASFV detection in a laboratory and on site, particularly ASFV detection in quarantine ports, airports and epidemic disease outbreak sites, and provides a novel and reliable technique support for ASF control in China.

The invention discloses an immunofluorescence detection test strip and a preparation method thereof for rapid quantitative detection of porcine epidemic diarrhea viruses. The test strip comprises a sample cushion, a combination cushion, a chromatography film and a water-absorbing cushion, wherein the combination cushion is provided with a fluorescent microsphere labelled anti-PEDV (Porcine Epidemic Diarrhea Viruses) single-domain antibody; the single-domain antibody has high specificity and high sensibility against the antigen PEDV. The test strip is used for detecting PEVD viruses in breeding pig manure or PEDV pollution in feeding stuff plasma proteins on the basis of the newfound immunology principle of the specific single-domain antibody and antigen, can be used for on-site rapid detection or laboratory detection by simply taking 5-10 min; when the test strip is used in combination with a fluorescence quantitative detector, quantitative detection can be realized; the test strip is simple and convenient to operate, operators don't need professional training, a special laboratory is not needed, the limitation of the conventional detection method is overcome, and the test strip has good market prospects.

The present invention relates to a method using adapter type reagent to detect, identify, and/or ration the compound. The present invention adopts the SELEX technology, uses various biologic molecules possessing the diagnosing value including the nucleotide sequence, the protein, the aminophenol, the polypeptide chain, the glucide, or the complete thalli as the target matters, and filters the corresponding high specificity adapter from which to obtain the target matters. The present invention has the advantages that the repeatability and the stability of the test result can be improved greatly, lots difference of the test can be reduced, and the reliability of the test result can be fully ensured. The present invention can be used to diagnose the clinic target molecular quickly and simply, and can provide favorable basis for the lab diagnosis. The present invention has short test time, low reagent cost, short research and development period, stable quality, etc.

The present invention provides a single self-contained device for collecting, extracting, on-site testing, and transferring for forensic confirmatory analysis, a wide variety of substances including, but not limited to, drugs of abuse, explosives, weapons of mass destruction, food toxins and industrial wastes. Samples can be obtained from a surface by swabbing a suspect area or the testing of solid materials (pills, capsules, powders), air samples and biological and non-biological fluids by placing the substance in the device. The device includes a swab, a retention well including a wash, and analysis technologies that can be, for example, a lateral flow testing system. The swab is rinsed with a wash prior to testing thereby not compromising the chemistry of the detection technologies and allowing for a wide variety of applications under a number of field conditions. Also, the device is a single self-contained unit instead of having a separate reagent droppers or sprays, making it compact and easy to use. Moreover, the device is designed to not only collect and test samples but to seal the originally target analyte, not affected by testing procedures, in a specially designed cap for shipping under chain of custody documentation to a forensic laboratory for confirmatory testing.

The invention relates to an SARS-CoV-2 neutralizing antibody detection kit. The SARS-CoV-2 neutralizing antibody detection kit comprises a solid phase carrier, a first antigen and a second antigen ofS protein of SARS-CoV-2, and the second antigen is marked with a signal substance. Whether a tested person is infected by the new coronavirus or not and whether infection risks exist or not are judgedby detecting a neutralizing antibody through an immunodiagnosis technology, and the method is reliable in theory, practical and feasible and can be completed only in a secondary biosafety laboratory.

The invention relates to the technical field of biology, particularly the field of viral antibody detection. A kit for detecting the antibody against Peste des petits ruminants virus b-ELISA comprises the following ingredients which are arranged respectively: Peste des petits ruminants nucleoprotein antigen, Peste des petits ruminants monoclonal antibody, diluent, strong positive serum, weak positive serum, negative serum, HRP sheep anti-mouse secondary antibody, 20 times the concentration of washing liquid, substrate liquid, stopping solution and enzyme-linked immunosorbent plate. The optimum proportion of each ingredient in the kit is determined by experiments. The kit can be used for rapid diagnosis and detection of animal Peste des petits ruminants virus antibody, especially for the antibody detection of a lot of samples in the epidemiological survey of Peste des petits ruminants. The detection method of Peste des petits ruminants virus b-ELISA has different detection principle and experiment operating procedures and the like from those of a c-ELISA detection method in a BIRAD laboratory. The Peste des petits ruminants nucleoprotein antigen and Peste des petits ruminants monoclonal antibody in the kit are self-developed. The detection sensitivity, singularity and other indexes of the kit are the same with those of the c-ELISA detection method in the internationally recognized BIRAD laboratory.

The invention provides a fluorescent quantitative reverse transcription-polymerase chain reaction (RT-PCR) kit for detecting an influenza A virus subtype H7N9. The fluorescent quantitative RT-PCR kit can be used for detection of influenza A viruses and the influenza A virus subtype H7N9. The fluorescent quantitative RT-PCR kit comprises a quantitative RT-PCR reaction solution, an enzyme mixed liquor, a primer and probe mixed liquor, standard substances of influenza A viruses, H7, N9 and RNaseP, positive reference substances of influenza A viruses, H7, N9 and RNaseP), and negative reference substances. Specific primers and probes are designed according to conserved sequences of influenza A viruses, H7 and N9. The RNaseP primers and probes are used as internal references. Through the one-step quadruple real-time fluorescent RT-PCR technology, the influenza A virus and the influenza A virus subtype H7N9 in the sample can be fast and accurately detected. The fluorescent quantitative RT-PCR kit has a reasonable design, very high singularity, sensitivity and repeatability, can be used for laboratory emergency diagnosis and fast screening of an epidemic disease caused by the influenza A virus subtype H7N9, and for an epidemiology study on the influenza A virus and the influenza A virus subtype H7N9 causing fever and respiratory tract syndrome.

The invention discloses a sepsis early prediction method based on machine learning. The method comprises the following steps: firstly, extracting clinical data, including demographic statistics (suchas age and gender), vital sign variables (such as heart rate and systolic pressure) and laboratory measurement indexes (such as creatinine and platelet count), of a patient within 24 hours after a patient enters an ICU by utilizing an electronic medical record, preprocessing the data, inputting the preprocessed data into an improved deep forest algorithm model for training, and outputting the disease probability of the patient after training optimization. And meanwhile, the algorithm model can also sort characteristic variables and output an early warning factor which has great influence on early prediction of sepsis. Finally, corresponding variables of the patient needing to be predicted are input into the trained model, so that early prediction of sepsis can be carried out on the patient. According to the invention, early prediction is carried out on sepsis based on a machine learning method, doctors can be assisted in making clinical decisions, and the prediction accuracy is improved.